Stock Track | Recursion Pharmaceuticals Soars 5.13% on Optimism Around Upcoming Clinical Milestones

Stock Track

Mar 08

Shares of Recursion Pharmaceuticals (RXRX) surged 5.13% in intraday trading on Friday, outperforming the broader market. The rally appears to be driven by investor optimism around the company's promising drug pipeline and upcoming clinical milestones in 2025.

Recursion is a pioneer in using artificial intelligence (AI) and machine learning to accelerate the drug discovery and development process. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful accelerated computing systems for evaluating millions of compounds and identifying potential drug candidates.

With 10 clinical and pre-clinical programs in areas like rare diseases, oncology, and neuroscience, Recursion has several potential catalysts on the horizon. Up to 10 programs are set to reach important data readouts, regulatory submissions, or trial initiations over the next 18 months. Successful outcomes could validate the company's technology and drive further gains in the stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1107514335"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107514335\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1107514335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-08 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107514335","market":"us","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Soars 5.13% on Optimism Around Upcoming Clinical Milestones","media":"Stock Track","content":"<p>Shares of Recursion Pharmaceuticals (RXRX) surged 5.13% in intraday trading on Friday, outperforming the broader market. The rally appears to be driven by investor optimism around the company's promising drug pipeline and upcoming clinical milestones in 2025.</p>\n\n<p>Recursion is a pioneer in using artificial intelligence (AI) and machine learning to accelerate the drug discovery and development process. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful accelerated computing systems for evaluating millions of compounds and identifying potential drug candidates.</p>\n\n<p>With 10 clinical and pre-clinical programs in areas like rare diseases, oncology, and neuroscience, Recursion has several potential catalysts on the horizon. Up to 10 programs are set to reach important data readouts, regulatory submissions, or trial initiations over the next 18 months. Successful outcomes could validate the company's technology and drive further gains in the stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Soars 5.13% on Optimism Around Upcoming Clinical Milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Soars 5.13% on Optimism Around Upcoming Clinical Milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-08 03:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Recursion Pharmaceuticals (RXRX) surged 5.13% in intraday trading on Friday, outperforming the broader market. The rally appears to be driven by investor optimism around the company's promising drug pipeline and upcoming clinical milestones in 2025.</p>\n\n<p>Recursion is a pioneer in using artificial intelligence (AI) and machine learning to accelerate the drug discovery and development process. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful accelerated computing systems for evaluating millions of compounds and identifying potential drug candidates.</p>\n\n<p>With 10 clinical and pre-clinical programs in areas like rare diseases, oncology, and neuroscience, Recursion has several potential catalysts on the horizon. Up to 10 programs are set to reach important data readouts, regulatory submissions, or trial initiations over the next 18 months. Successful outcomes could validate the company's technology and drive further gains in the stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1107514335","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107514335","pubTimestamp":1741375461,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Recursion Pharmaceuticals  surged 5.13% in intraday trading on Friday, outperforming the broader market. The rally appears to be driven by investor optimism around the company's promising drug pipeline and upcoming clinical milestones in 2025.Recursion is a pioneer in using artificial intelligence  and machine learning to accelerate the drug discovery and development process. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful accelera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"由于对即将到来的临床里程碑持乐观态度，Recursion Pharmaceuticals股价飙升5.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Shares of Recursion Pharmaceuticals (RXRX) surged 5.13% in intraday trading on Friday, outperforming the broader market. The rally appears to be driven by investor optimism around the company's promising drug pipeline and upcoming clinical milestones in 2025.\nRecursion is a pioneer in using artificial intelligence (AI) and machine learning to accelerate the drug discovery and development process. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful accelerated computing systems for evaluating millions of compounds and identifying potential drug candidates.\nWith 10 clinical and pre-clinical programs in areas like rare diseases, oncology, and neuroscience, Recursion has several potential catalysts on the horizon. Up to 10 programs are set to reach important data readouts, regulatory submissions, or trial initiations over the next 18 months. Successful outcomes could validate the company's technology and drive further gains in the stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}